Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be Neurocrine's stock price by end of 2024?
Above $100 • 25%
$75 to $100 • 25%
$50 to $75 • 25%
Below $50 • 25%
Stock price data from major financial news websites or stock exchanges
Neurocrine's Schizophrenia Drug Shows 7.5 Point Improvement in Phase 2 Trial; Shares Drop 15.6%
Aug 28, 2024, 11:33 AM
Neurocrine Biosciences has announced positive results from a mid-stage Phase 2 study of its experimental drug NBI-1117568 for treating schizophrenia in adults. The study achieved its main goal, showing a 7.5 point improvement on the PANSS score with a 20 mg daily dose, which was statistically significant. However, no improvement was observed with higher doses. Despite the positive outcome, the company's shares have dropped by 15.6% in pre-market trading as investors reacted to the mixed results of the trial.
View original story
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $2 • 25%
$2 to $5 • 25%
Above $10 • 25%
Below $5 • 25%
$5 to $10 • 25%
$10 to $15 • 25%
Above $15 • 25%
Below $50 • 25%
$50-$74.99 • 25%
$75-$99.99 • 25%
$100 or higher • 25%
Below $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
Above $40 • 25%
Less than $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
More than $40 • 25%
Above $25 • 25%
$20 - $25 • 25%
$15 - $20 • 25%
Below $15 • 25%
Below $200 • 25%
$200 to $250 • 25%
$250 to $300 • 25%
Above $300 • 25%
Above $500 • 25%
Between $400 and $500 • 25%
Between $300 and $400 • 25%
Below $300 • 25%
Above $600 • 25%
$500 to $600 • 25%
$400 to $500 • 25%
Below $400 • 25%
$400-$500 • 25%
$500-$600 • 25%
Above $600 • 25%
$500 - $600 • 25%
$400 - $500 • 25%
Below $400 • 25%
Above $150 • 25%
$120 to $150 • 25%
$100 to $120 • 25%
Below $100 • 25%
Below $140 • 25%
$140 to $150 • 25%
$150 to $160 • 25%
Above $160 • 25%
$140 to $160 • 25%
$160 to $180 • 25%
Above $180 • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Remain within 10% of current price • 25%
Decrease by more than 10% • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Approved at higher dose • 25%
Not approved • 25%
Approved at 20 mg dose • 25%
Approved at multiple doses • 25%